title: [Pharma-clinics how I treat ... an HIV infection. IV. Protease inhibitors].
abstract: Protease inhibitors constitute the last class of antiretroviral drugs appeared on the market. They raised an enormous enthusiasm, reinforced by recent studies results. These molecules prevent the formation of infectious viral particles, while inhibiting a viral enzyme that plays a key role in the cycle of replication of the HIV. Their efficiency, especially in association, is recognized for all stages of the infection and the intervening of a resistance often requires many mutations. However, the unexpected adverse events such as lipodystrophy and some interactions can limit their utilization in first intention.
authors.affiliation: Service de Médecine interne, Université de Liège.
authors.forename: P
authors.initials: P
authors.lastname: Léonard
authors.forename: D
authors.initials: D
authors.lastname: Nkoghe
authors.forename: M
authors.initials: M
authors.lastname: Moutschen
authors.forename: J
authors.initials: J
authors.lastname: Demonty
mesh_terms: D002453:Cell Cycle; D004351:Drug Resistance; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008060:Lipodystrophy / Q000139:chemically induced; D011480:Protease Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D011480:Protease Inhibitors